testosterone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
androgens/anabolic steroids	2607	58-22-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: testosterone 17beta-Testosterone	A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. Molecular weight: 288.43 Formula: C19H28O2 CLOGP: 3.41 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 37.30 ALOGS: -3.94 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

testosterone
17beta-Testosterone

A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.

Molecular weight: 288.43
Formula: C19H28O2
CLOGP: 3.41
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 37.30
ALOGS: -3.94
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.12	g	O
18	mg	P
0.12	g	R
60	mg	SL
50	mg	TD
3	mg	TD

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.02 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.97 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	4 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.35 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	24.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.06 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.17 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 13, 1972	FDA	ACTIENT PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood testosterone increased	262.82	22.43	36	2711	117	46683198
Accidental exposure to product	243.18	22.43	77	2670	21004	46662311
Expulsion of medication	145.05	22.43	17	2730	4	46683311
Virilism	135.89	22.43	17	2730	19	46683296
Precocious puberty	119.70	22.43	19	2728	200	46683115
Enlarged clitoris	118.53	22.43	18	2729	138	46683177
Hair growth abnormal	113.40	22.43	27	2720	2531	46680784
Accidental exposure to product by child	61.09	22.43	14	2733	1109	46682206
Off label use	59.99	22.43	91	2656	379750	46303565
Renal infarct	44.38	22.43	11	2736	1216	46682099
Metaplasia	42.92	22.43	9	2738	471	46682844
Skin laceration	42.31	22.43	21	2726	18481	46664834
Hirsutism	41.49	22.43	10	2737	984	46682331
Atherosclerotic plaque rupture	41.36	22.43	5	2742	3	46683312
Infertility	40.31	22.43	9	2738	633	46682682
Borderline serous tumour of ovary	37.89	22.43	5	2742	11	46683304
Blood testosterone decreased	31.12	22.43	5	2742	57	46683258
Vaginal disorder	29.17	22.43	7	2740	676	46682639
Chorioretinopathy	28.60	22.43	7	2740	734	46682581
Acne	27.03	22.43	16	2731	19903	46663412
Apocrine breast carcinoma	26.22	22.43	3	2744	0	46683315
Breast cancer	24.99	22.43	21	2726	45497	46637818
Focal segmental glomerulosclerosis	24.09	22.43	7	2740	1414	46681901
Adnexal torsion	24.08	22.43	5	2742	249	46683066
Libido increased	23.35	22.43	6	2741	766	46682549
Exposure via skin contact	23.30	22.43	4	2743	70	46683245
Osteonecrosis	23.27	22.43	16	2731	25728	46657587

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood testosterone decreased	1397.41	11.56	394	28569	4002	29919513
Blood testosterone increased	465.60	11.56	122	28841	910	29922605
Polycythaemia	269.37	11.56	90	28873	1662	29921853
Application site rash	239.29	11.56	69	28894	760	29922755
Product administered at inappropriate site	235.61	11.56	80	28883	1555	29921960
Deep vein thrombosis	196.09	11.56	266	28697	60235	29863280
Expulsion of medication	177.89	11.56	32	28931	15	29923500
Product deposit	177.57	11.56	43	28920	222	29923293
Blood testosterone abnormal	173.57	11.56	42	28921	216	29923299
Incorrect dose administered	159.19	11.56	174	28789	31512	29892003
Haematocrit increased	144.05	11.56	56	28907	1620	29921895
Application site pain	133.90	11.56	53	28910	1610	29921905
Pulmonary embolism	126.44	11.56	251	28712	77884	29845631
Precocious puberty	117.81	11.56	26	28937	81	29923434
Implant site pain	117.11	11.56	27	28936	108	29923407
Prescribed overdose	114.41	11.56	82	28881	8479	29915036
Application site erythema	114.10	11.56	52	28911	2251	29921264
Testicular atrophy	96.71	11.56	31	28932	499	29923016
Infertility male	86.88	11.56	23	28940	179	29923336
Toxicity to various agents	85.98	11.56	32	28931	177151	29746364
Application site pruritus	83.90	11.56	36	28927	1347	29922168
Insulin-like growth factor increased	83.19	11.56	33	28930	1008	29922507
Libido decreased	83.17	11.56	53	28910	4513	29919002
Product quality issue	80.48	11.56	95	28868	18679	29904836
Death	75.29	11.56	145	28818	357138	29566377
Product odour abnormal	73.46	11.56	26	28937	574	29922941
Application site reaction	73.01	11.56	24	28939	420	29923095
Pituitary tumour benign	68.46	11.56	27	28936	812	29922703
Gynaecomastia	64.47	11.56	58	28905	8293	29915222
Craniopharyngioma	64.32	11.56	20	28943	290	29923225
Blood testosterone free decreased	63.72	11.56	15	28948	67	29923448
Hypogonadism	60.86	11.56	29	28934	1390	29922125
Erectile dysfunction	60.67	11.56	81	28882	18021	29905494
Prostatic specific antigen increased	60.37	11.56	66	28897	11938	29911577
Febrile neutropenia	59.38	11.56	15	28948	106678	29816837
Application site exfoliation	57.93	11.56	15	28948	106	29923409
Oestradiol increased	55.75	11.56	12	28951	32	29923483
Application site irritation	54.76	11.56	22	28941	695	29922820
Neutropenia	54.72	11.56	28	28935	128512	29795003
Azoospermia	54.39	11.56	19	28944	403	29923112
Hair growth abnormal	53.51	11.56	21	28942	623	29922892
Application site dryness	52.66	11.56	12	28951	45	29923470
Secondary hypogonadism	52.22	11.56	17	28946	288	29923227
Device expulsion	51.34	11.56	13	28950	83	29923432
Performance enhancing product use	49.70	11.56	13	28950	96	29923419
Osteonecrosis	49.23	11.56	69	28894	16066	29907449
Haemoglobin increased	48.71	11.56	32	28931	2870	29920645
Completed suicide	48.14	11.56	18	28945	99474	29824041
Application site vesicles	48.09	11.56	19	28944	574	29922941
Feeling abnormal	48.01	11.56	142	28821	56614	29866901
Poor quality product administered	47.89	11.56	26	28937	1643	29921872
Thrombocytopenia	47.21	11.56	38	28925	137006	29786509
General physical health deterioration	46.84	11.56	19	28944	99925	29823590
Muscle mass	46.31	11.56	15	28948	250	29923265
Clear cell renal cell carcinoma	46.05	11.56	21	28942	910	29922605
Red blood cell count increased	45.90	11.56	24	28939	1405	29922110
Focal segmental glomerulosclerosis	45.69	11.56	26	28937	1801	29921714
Implant site bruising	45.00	11.56	8	28955	3	29923512
Drug ineffective	44.85	11.56	514	28449	339873	29583642
Hyperoestrogenism	43.66	11.56	8	28955	5	29923510
Implant site infection	42.96	11.56	20	28943	909	29922606
Pyrexia	42.92	11.56	144	28819	294345	29629170
Sleep apnoea syndrome	41.25	11.56	65	28898	16792	29906723
Wrong technique in product usage process	40.90	11.56	92	28871	31063	29892452
Acute myocardial infarction	40.60	11.56	128	28835	52811	29870704
Prostate cancer	39.91	11.56	78	28885	23879	29899636
Cerebrovascular accident	38.99	11.56	172	28791	83305	29840210
Insulin-like growth factor decreased	38.16	11.56	13	28950	255	29923260
Infertility	37.97	11.56	12	28951	184	29923331
Thrombosis	36.98	11.56	107	28856	42124	29881391
Drug abuse	36.74	11.56	167	28796	81905	29841610
Application site discolouration	36.29	11.56	12	28951	214	29923301
Acne	35.95	11.56	45	28918	9391	29914124
Anaemia	35.06	11.56	95	28868	207897	29715618
Acute kidney injury	34.57	11.56	142	28821	273700	29649815
Drug interaction	34.51	11.56	90	28873	199478	29724037
Application site urticaria	33.89	11.56	9	28954	71	29923444
Mesenteric vein thrombosis	32.92	11.56	14	28949	512	29923003
Blood oestrogen increased	32.92	11.56	8	28955	42	29923473
Product container issue	32.69	11.56	16	28947	814	29922701
Myocardial infarction	32.31	11.56	220	28743	125405	29798110
Drug-disease interaction	31.07	11.56	11	28952	243	29923272
Blood testosterone free increased	29.78	11.56	6	28957	10	29923505
Virilism	29.71	11.56	5	28958	0	29923515
Product administration error	29.22	11.56	51	28912	14326	29909189
Interstitial lung disease	28.92	11.56	11	28952	60186	29863329
Product physical consistency issue	28.83	11.56	11	28952	302	29923213
Pancytopenia	28.74	11.56	24	28939	85028	29838487
Sepsis	28.48	11.56	62	28901	146333	29777182
Headache	28.40	11.56	285	28678	182021	29741494
Product dose omission issue	28.20	11.56	168	28795	91463	29832052
Lymphoproliferative disorder	28.14	11.56	21	28942	2309	29921206
Implant site haemorrhage	27.91	11.56	8	28955	86	29923429
Breast cancer	27.76	11.56	11	28952	335	29923180
Implant site swelling	27.19	11.56	8	28955	95	29923420
Product physical issue	27.16	11.56	20	28943	2154	29921361
Septic shock	26.82	11.56	14	28949	63593	29859922
Pneumonia	26.54	11.56	202	28761	334104	29589411
Malignant neoplasm progression	26.19	11.56	19	28944	72268	29851247
Depression	26.05	11.56	163	28800	90274	29833241
Coronary artery disease	25.95	11.56	106	28857	49606	29873909
Myocardial fibrosis	25.73	11.56	13	28950	708	29922807
Left ventricular hypertrophy	25.63	11.56	31	28932	6247	29917268
Hyperhidrosis	25.31	11.56	130	28833	66960	29856555
Stubbornness	25.10	11.56	6	28957	29	29923486
Pituitary tumour recurrent	25.06	11.56	7	28956	68	29923447
Muscle hypertrophy	24.93	11.56	6	28957	30	29923485
Anger	24.64	11.56	41	28922	11079	29912436
Product storage error	23.59	11.56	30	28933	6361	29917154
Application site dermatitis	23.34	11.56	6	28957	41	29923474
Fatigue	23.30	11.56	437	28526	320236	29603279
Hypogonadism male	23.19	11.56	9	28954	259	29923256
Renal failure	23.16	11.56	57	28906	128909	29794606
Acne fulminans	23.06	11.56	8	28955	166	29923349
Neoplasm recurrence	22.93	11.56	17	28946	1850	29921665
Insulin resistance	22.63	11.56	11	28952	551	29922964
Cholelithiasis	22.49	11.56	56	28907	20169	29903346
Blood follicle stimulating hormone decreased	22.30	11.56	6	28957	50	29923465
Blood luteinising hormone decreased	21.70	11.56	7	28956	115	29923400
Hypotension	21.69	11.56	110	28853	200455	29723060
Loss of libido	21.58	11.56	17	28946	2025	29921490
Melaena	21.34	11.56	3	28960	32434	29891081
Stomatitis	21.19	11.56	5	28958	37274	29886241
Injection site pain	21.16	11.56	71	28892	30239	29893276
Treatment failure	21.04	11.56	4	28959	34675	29888840
Intentional overdose	20.91	11.56	7	28956	41474	29882041
Hypercoagulation	20.88	11.56	13	28950	1062	29922453
Pituitary tumour	20.80	11.56	10	28953	489	29923026
Hormone level abnormal	20.79	11.56	9	28954	344	29923171
Decreased appetite	20.62	11.56	75	28888	149835	29773680
Renal infarct	20.30	11.56	13	28950	1116	29922399
Implant site erythema	20.18	11.56	6	28957	74	29923441
Multiple organ dysfunction syndrome	20.14	11.56	19	28944	63468	29860047
Application site paraesthesia	20.11	11.56	4	28959	6	29923509
Glucose tolerance decreased	19.97	11.56	6	28957	77	29923438
Therapeutic response unexpected	19.96	11.56	33	28930	8870	29914645
Breast tenderness	19.89	11.56	11	28952	721	29922794
Platelet count decreased	19.77	11.56	46	28917	106083	29817432
Chorioretinopathy	19.60	11.56	14	28949	1438	29922077
Cardio-respiratory arrest	19.56	11.56	16	28947	57290	29866225
Oligospermia	19.55	11.56	6	28957	83	29923432
Product complaint	19.47	11.56	26	28937	5780	29917735
Accidental exposure to product	19.41	11.56	35	28928	10080	29913435
Skin irritation	19.27	11.56	22	28941	4170	29919345
Cardiac death	18.83	11.56	12	28951	1021	29922494
Leukopenia	18.78	11.56	16	28947	56143	29867372
Implant site mass	18.77	11.56	4	28959	10	29923505
Factor V Leiden mutation	18.49	11.56	4	28959	11	29923504
Transient ischaemic attack	18.46	11.56	60	28903	25140	29898375
Expired product administered	18.44	11.56	18	28945	2851	29920664
Cardiac failure	18.21	11.56	33	28930	83385	29840130
Confusional state	18.18	11.56	68	28895	134766	29788749
Blood growth hormone increased	18.12	11.56	7	28956	199	29923316
Application site inflammation	17.94	11.56	6	28957	111	29923404
Acromegaly	17.86	11.56	5	28958	49	29923466
Angiofibroma	17.83	11.56	3	28960	0	29923515
C-reactive protein increased	17.70	11.56	10	28953	43463	29880052
Growth hormone-producing pituitary tumour	17.55	11.56	4	28959	15	29923500
Prostatomegaly	17.49	11.56	22	28941	4614	29918901
Needle issue	17.43	11.56	20	28943	3812	29919703
Spinal cord abscess	17.40	11.56	7	28956	222	29923293
Portal vein thrombosis	17.33	11.56	19	28944	3445	29920070
Thyroxine decreased	17.32	11.56	6	28957	124	29923391
Acne conglobata	17.15	11.56	4	28959	17	29923498
Growth accelerated	17.15	11.56	4	28959	17	29923498
Amnesia	17.00	11.56	57	28906	24264	29899251
Obesity	16.93	11.56	30	28933	8525	29914990
Bone marrow failure	16.92	11.56	4	28959	29781	29893734
Application site burn	16.67	11.56	7	28956	248	29923267
Gastrointestinal haemorrhage	16.49	11.56	35	28928	83411	29840104
Disease progression	16.21	11.56	33	28930	79841	29843674
Cerebral venous thrombosis	16.16	11.56	9	28954	598	29922917
Underdose	16.09	11.56	36	28927	12105	29911410
Bradycardia	16.09	11.56	24	28939	65502	29858013
Circumstance or information capable of leading to medication error	16.09	11.56	13	28950	1606	29921909
Aortic aneurysm	16.06	11.56	25	28938	6388	29917127
Anorgasmia	16.05	11.56	9	28954	606	29922909
Liquid product physical issue	15.92	11.56	7	28956	278	29923237
Implant site cellulitis	15.87	11.56	4	28959	25	29923490
Implant site necrosis	15.75	11.56	3	28960	3	29923512
Dermal absorption impaired	15.75	11.56	3	28960	3	29923512
Mucosal inflammation	15.62	11.56	5	28958	30489	29893026
Stress	15.56	11.56	49	28914	20186	29903329
Penis disorder	15.48	11.56	11	28952	1121	29922394
Hyperkalaemia	15.42	11.56	25	28938	65985	29857530
Testis discomfort	15.29	11.56	3	28960	4	29923511
Sperm concentration zero	15.29	11.56	3	28960	4	29923511
Testicular pain	15.27	11.56	16	28947	2756	29920759
Blood thyroid stimulating hormone decreased	14.72	11.56	13	28950	1814	29921701
Retinal vein occlusion	14.40	11.56	12	28951	1547	29921968
Irritability	14.36	11.56	52	28911	22998	29900517
Intentional product misuse	14.36	11.56	69	28894	34598	29888917
Hepatic adenoma	14.31	11.56	4	28959	39	29923476
Congestive cardiomyopathy	14.11	11.56	24	28939	6603	29916912
Thrombophlebitis superficial	13.98	11.56	15	28948	2654	29920861
Ophthalmic vein thrombosis	13.96	11.56	4	28959	43	29923472
Orchidectomy	13.63	11.56	4	28959	47	29923468
Empty sella syndrome	13.48	11.56	4	28959	49	29923466
Drug withdrawal syndrome	13.47	11.56	46	28917	19763	29903752
Nipple pain	13.31	11.56	8	28955	614	29922901
Dehydration	13.19	11.56	68	28895	123471	29800044
Neutrophil count decreased	13.12	11.56	13	28950	42441	29881074
Eye colour change	13.03	11.56	6	28957	266	29923249
Skin odour abnormal	12.92	11.56	9	28954	888	29922627
Sperm concentration decreased	12.91	11.56	5	28958	143	29923372
Mood swings	12.90	11.56	25	28938	7601	29915914
Thyrotoxic periodic paralysis	12.68	11.56	4	28959	61	29923454
Gastric hypomotility	12.56	11.56	4	28959	63	29923452
Device extrusion	12.47	11.56	3	28960	15	29923500
Drug reaction with eosinophilia and systemic symptoms	12.41	11.56	6	28957	28482	29895033
Hyperglycaemic hyperosmolar nonketotic syndrome	12.26	11.56	9	28954	965	29922550
Pollakiuria	12.15	11.56	40	28923	16866	29906649
Astrocytoma	11.96	11.56	5	28958	175	29923340
Dyspnoea	11.95	11.56	239	28724	333056	29590459
Cardiomyopathy	11.95	11.56	37	28926	15106	29908409
Autoimmune thyroiditis	11.89	11.56	9	28954	1011	29922504
Diarrhoea	11.85	11.56	240	28723	333863	29589652
Cardiac arrest	11.76	11.56	48	28915	92802	29830713
Penile size reduced	11.73	11.56	5	28958	184	29923331
Carotid artery occlusion	11.72	11.56	12	28951	2013	29921502
Gamma-glutamyltransferase increased	11.59	11.56	7	28956	29343	29894172
Oxygen saturation decreased	11.57	11.56	15	28948	43425	29880090

Pharmacologic Action:

Source	Code	Description
ATC	G03BA03	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS 3-oxoandrosten (4) derivatives
ATC	G03EA02	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION Androgens and estrogens
FDA CS	M0001109	Androstanes
FDA MoA	N0000000146	Androgen Receptor Agonists
FDA EPC	N0000175824	Androgen
MeSH PA	D000728	Androgens
MeSH PA	D006728	Hormones
CHEBI has role	CHEBI:50113	androgens
CHEBI has role	CHEBI:75771	mus musculus metabolite
CHEBI has role	CHEBI:77746	h. sapiens metabolites
CHEBI has role	CHEBI:83056	daphnia magna metabolites

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Hypogonadotropic hypogonadism	indication	33927004
Deficiency of testosterone biosynthesis	indication	38825009
Inhibition of lactation procedure	indication	43141007
Male hypogonadism	indication	48723006
Hypopituitarism	indication	74728003	DOID:9406
Menopausal flushing	indication	198436008
Undescended testicle	indication	204878001	DOID:11383
Bilateral orchidectomy	indication	386634006
Delayed puberty	indication	400003000
Klinefelter's syndrome, XXY	indication	405769009
Hormone receptor positive malignant neoplasm of breast	indication	417181009
Primary Hypogonadism due to Bilateral Torsion	indication
Primary Hypogonadism due to Orchitis	indication
LHRH Deficiency	indication
Chemotherapy-Induced Hypogonadism	indication
Bilateral Anorchia	indication
Noonan's syndrome	off-label use	205824006	DOID:3490
Hyperlipoproteinemia	contraindication	3744001	DOID:1168
Gynecomastia	contraindication	4754008	DOID:12698
Hypocalcemia	contraindication	5291005
Hypercholesterolemia	contraindication	13644009
Myocardial infarction	contraindication	22298006	DOID:5844
Chloasma	contraindication	36209000
Migraine	contraindication	37796009	DOID:6364
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Body fluid retention	contraindication	43498006
Thrombosis of retinal vein	contraindication	46085004
Humoral hypercalcemia of malignancy	contraindication	47709007
Chronic heart failure	contraindication	48447003
Dementia	contraindication	52448006
Hepatic porphyria	contraindication	55056006	DOID:3133
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Heart disease	contraindication	56265001	DOID:114
Thrombophlebitis	contraindication	64156001	DOID:3875
Intermenstrual bleeding - irregular	contraindication	64996003
Hypercalcemia	contraindication	66931009	DOID:12678
Arteriosclerotic vascular disease	contraindication	72092001
Diabetes mellitus	contraindication	73211009	DOID:9351
Sleep apnea	contraindication	73430006	DOID:0050847
Heart failure	contraindication	84114007	DOID:6000
Epilepsy	contraindication	84757009	DOID:1826
Breast lump	contraindication	89164003
Kidney disease	contraindication	90708001	DOID:557
Uterine leiomyoma	contraindication	95315005	DOID:13223
Magnetic resonance imaging	contraindication	113091000
Neoplasm of liver	contraindication	126851005	DOID:3571
Neoplasm of prostate	contraindication	126906006	DOID:10283
Deep venous thrombosis	contraindication	128053003
Endometriosis	contraindication	129103003
Mammography abnormal	contraindication	168750009
Asthma	contraindication	195967001	DOID:2841
Cerebrovascular accident	contraindication	230690007
Pulmonary thromboembolism	contraindication	233935004
Thrombophilia	contraindication	234467004	DOID:2452
Disease of liver	contraindication	235856003	DOID:409
Endometrial carcinoma	contraindication	254878006	DOID:2871
Benign prostatic hyperplasia	contraindication	266569009
Edema	contraindication	267038008
Chorea	contraindication	271700006
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Functional visual loss	contraindication	313165001
Malignant tumor of ovary	contraindication	363443007	DOID:2394
Thromboembolic disorder	contraindication	371039008
Cardiovascular event risk	contraindication	395112001
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Obesity	contraindication	414916001	DOID:9970
Estrogen receptor positive tumor	contraindication	416053008
Family history of malignant neoplasm of breast	contraindication	429740004
Hypertensive urgency	contraindication	443482000
Carcinoma of female breast	contraindication	447782002
Smokes tobacco daily	contraindication	449868002
Breast Carcinoma in Males	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN	AGONIST	EC50	9.20	WOMBAT-PK	CHEMBL
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	5.84	DRUG MATRIX
Aromatase	Enzyme	P11511	CP19A_HUMAN		Ki	6.22	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	5.92	CHEMBL
Sex hormone-binding globulin	Secreted	P04278	SHBG_HUMAN		Kd	9.20	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme	Q16850	CP51A_HUMAN		IC50	4.30	CHEMBL
Corticosteroid-binding globulin	Secreted	P08185	CBG_HUMAN		Ki	6.72	CHEMBL
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	6.60	DRUG MATRIX
Steroid 5-alpha-reductase	Enzyme		S5A1_RAT S5A2_RAT		IC50	5.72	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	8.85	CHEMBL
Constitutive androstane receptor	Unclassified		NR1I3_MOUSE		IC50	4.52	CHEMBL
C-8 sterol isomerase	Enzyme		ERG2_YEAST		Ki	5.11	CHEMBL

External reference:

ID	Source
4017484	VUID
N0000145872	NUI
D00075	KEGG_DRUG
4017484	VANDF
C0039601	UMLSCUI
CHEBI:17347	CHEBI
TES	PDB_CHEM_ID
CHEMBL386630	ChEMBL_ID
CHEMBL1201101	ChEMBL_ID
D013739	MESH_DESCRIPTOR_UI
1900	INN_ID
DB00624	DRUGBANK_ID
3XMK78S47O	UNII
6013	PUBCHEM_CID
2858	IUPHAR_LIGAND_ID
10379	RXNORM
2966	MMSL
5552	MMSL
d00558	MMSL
001245	NDDF
109033004	SNOMEDCT_US
43688007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Androderm	HUMAN PRESCRIPTION DRUG LABEL	1	0023-5990	PATCH	2 mg	TRANSDERMAL	NDA	34 sections
Androderm	HUMAN PRESCRIPTION DRUG LABEL	1	0023-5992	PATCH	4 mg	TRANSDERMAL	NDA	34 sections
Androgel	HUMAN PRESCRIPTION DRUG LABEL	1	0051-8425	GEL	10 mg	TRANSDERMAL	NDA	30 sections
Androgel	HUMAN PRESCRIPTION DRUG LABEL	1	0051-8450	GEL	10 mg	TRANSDERMAL	NDA	30 sections
Androgel	HUMAN PRESCRIPTION DRUG LABEL	1	0051-8462	GEL	16.20 mg	TRANSDERMAL	NDA	29 sections
Androgel	HUMAN PRESCRIPTION DRUG LABEL	1	0051-8488	GEL	10 mg	TRANSDERMAL	NDA	30 sections
Vogelxo	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0871	GEL	50 mg	TOPICAL	NDA	37 sections
Vogelxo	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0872	GEL, METERED	12.50 mg	TOPICAL	NDA	37 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0254-1012	GEL	50 mg	TRANSDERMAL	NDA AUTHORIZED GENERIC	33 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2114	SOLUTION	30 mg	TOPICAL	ANDA	33 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2363	GEL, METERED	10 mg	TOPICAL	ANDA	33 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2921	GEL	10 mg	TOPICAL	ANDA	32 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2924	GEL	16.20 mg	TRANSDERMAL	ANDA	32 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2925	GEL	16.20 mg	TRANSDERMAL	ANDA	32 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2926	GEL	16.20 mg	TRANSDERMAL	ANDA	32 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3216	GEL	10 mg	TOPICAL	ANDA	32 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3217	GEL	10 mg	TOPICAL	ANDA	32 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3524	GEL	50 mg	TRANSDERMAL	ANDA	30 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0603-7831	GEL, METERED	10 mg	TOPICAL	NDA AUTHORIZED GENERIC	34 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1120	GEL	50 mg	TOPICAL	NDA authorized generic	35 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1121	GEL, METERED	12.50 mg	TOPICAL	NDA authorized generic	35 sections
Testim	HUMAN PRESCRIPTION DRUG LABEL	1	16590-853	GEL	50 mg	TOPICAL	NDA	13 sections
testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-967	GEL	20.25 mg	TOPICAL	ANDA	33 sections
testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-968	GEL	20.25 mg	TOPICAL	ANDA	33 sections
testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-969	GEL	40.50 mg	TOPICAL	ANDA	33 sections
Androgel	HUMAN PRESCRIPTION DRUG LABEL	1	21695-112	GEL	10 mg	TRANSDERMAL	NDA	18 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	24979-078	GEL	16.20 mg	TRANSDERMAL	ANDA	29 sections
Natestonasal gel	HUMAN PRESCRIPTION DRUG LABEL	1	42667-5511	GEL, METERED	5.50 mg	NULLSAL	NDA	33 sections
Testosterone	HUMAN PRESCRIPTION DRUG LABEL	1	43598-304	GEL, METERED	1.62 mg	TRANSDERMAL	ANDA	31 sections
Testopel	HUMAN PRESCRIPTION DRUG LABEL	1	43773-1001	PELLET	75 mg	SUBCUTANEOUS	ANDA	12 sections